Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Migraine

  Free Subscription


25.02.2019

3 Cephalalgia
1 Headache
1 Lancet Neurol
1 Nat Rev Neurol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Cephalalgia

  1. XU D, Chen D, Zhu LN, Tan G, et al
    Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials.
    Cephalalgia. 2019 Feb 21:333102419829007. doi: 10.1177/0333102419829007.
    PubMed     Text format     Abstract available

  2. SENG EK, Gelfand AA, Nicholson RA
    Assessing evidence-based medicine and opioid/barbiturate as first-line acute treatment of pediatric migraine and primary headache: A retrospective observational study of health systems data.
    Cephalalgia. 2019 Feb 20:333102419833080. doi: 10.1177/0333102419833080.
    PubMed     Text format     Abstract available

  3. BOGDANOV VB, Bogdanova OV, Vigano A, Noirhomme Q, et al
    Increased cerebral responses to salient transitions between alternating stimuli in chronic migraine with medication overuse headache and during migraine attacks.
    Cephalalgia. 2019 Feb 20:333102418825359. doi: 10.1177/0333102418825359.
    PubMed     Text format     Abstract available


    Headache

  4. GRINBERG AS, Seng EK
    Cross-Sectional Evaluation of the Psychometric Properties of the Headache-Specific Locus of Control Scale in People With Migraine.
    Headache. 2019 Feb 19. doi: 10.1111/head.13485.
    PubMed     Text format     Abstract available


    Lancet Neurol

  5. THE LANCET NEUROLOGY
    Complicated decisions on new migraine-prevention therapies.
    Lancet Neurol. 2019;18:221.
    PubMed     Text format    


    Nat Rev Neurol

  6. KELSEY R
    Iron deposition in periaqueductal grey matter as a biomarker of chronic migraine.
    Nat Rev Neurol. 2019 Feb 18. pii: 10.1038/s41582-019-0151.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Migraine is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: